All In Biotech

Drug Trial Radar · NCT07713290

A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma

An Open-Label, Multiple-Dose Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

6

Actual

Start

Apr 3, 2025

Primary completion

Nov 12, 2026

Study completion Feb 28, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b study of GKL-006 Injection in patients with unresectable hepatocellular carcinoma.

Conditions

  • Hepatocellular Carcinoma (HCC)
  • Unresectable Hepatocellular Cancer

Interventions

  • GKL-006 InjectionDrug

    An iNKT cell therapy

  • Transarterial chemoembolization (TACE)Procedure

    A standard locoregional therapy for hepatocellular carcinoma

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Treatment-Related Adverse Events and Safety/Tolerability RisksTime frame: From the start of study treatment through 14 days after the fourth treatment; treatment-related adverse events will continue to be assessed according to the study protocol.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing You An Hospital

    Beijing, Beijing Municipality, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.